Position in MRNA
as of Mar 31, 2026
· filed May 6, 2026
Position Value
$595,833
+$250,417 QoQ
Shares Held
11,729
+0.1% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
10 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in MRNA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Annis Gardner Whiting Capital Advisors, LLC holds $3,080,551 across 24 Biotechnology names. MRNA ranks #3 (19.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
12,801 | $961,227 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,925 | $859,589 | |
| 3 | MRNA |
Moderna, Inc.
This page
|
11,729 | $595,833 | |
| 4 | IOVA |
Iovance Biotherapeutics, Inc.
|
100,400 | $352,404 | |
| 5 | EVAX |
Evaxion A/S
|
30,000 | $111,600 | |
| 6 | TECH |
BIO-TECHNE Corp
|
1,299 | $67,885 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
53 | $40,949 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
700 | $22,778 |
All Filings in MRNA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $595,833 | 11,729 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $345,416 | 11,713 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $300,945 | 11,651 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $293,943 | 10,654 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $213,447 | 7,529 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $226,236 | 5,441 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $315,170 | 4,716 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $525,231 | 4,423 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $319 | 3 | Shares | Sole | 2024-05-13 | |
| 2023-09-30 | $2,478 | 24 | Shares | Sole | 2023-11-08 | |
| No filing history on record for this holder in this stock. | ||||||